Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Pathology · Gastric Neuroendocrine Tumor

Decoding Your Pathology: Grading and Staging Your G-NET

At a Glance

Your G-NET pathology report determines how your tumor behaves using three main factors: differentiation (how abnormal cells look), grade (how fast they divide, measured by Ki-67 and mitotic rate), and stage (how far it has spread). These details are essential for guiding your treatment.

Your pathology report is the most important document in your medical record. It is the result of a pathologist looking at your tissue under a microscope to determine exactly what the “personality” of your tumor is. For gastric neuroendocrine tumors (G-NETs), the report must answer three main questions: What kind of cell is it? How fast is it growing? And how far has it gone? [1][2]

1. Differentiation: The “Family”

The first thing to look for is differentiation. This describes how much the tumor cells look like healthy, normal cells.

  • Well-Differentiated (NET): These tumors look fairly similar to normal hormone-producing cells. They are typically less aggressive and have a better prognosis [3][4]. Note: Even well-differentiated tumors can sometimes grow quickly (NET G3), but they are still biologically distinct from poorly differentiated tumors.
  • Poorly Differentiated (NEC): These cells look very abnormal and disorganized. By definition, all poorly differentiated tumors are high-grade and aggressive “carcinomas” (NECs) [5][6].

2. Grade: The “Speed”

Grading tells you how fast the tumor cells are dividing. This is measured in two ways:

  • Ki-67 Index: This is a “proliferation marker.” Pathologists use a special stain to see what percentage of cells are in the process of dividing. A Ki-67 of 2% means 2 out of every 100 cells are dividing [7][6].
  • Mitotic Rate: This is a manual count of how many cells are caught in the middle of dividing (mitosis) within a specific area of the slide [3].

The WHO 2019 Grading Scale for Gastric NETs:

Grade Ki-67 Index Mitotic Rate Growth Speed
G1 (Low) < 3% < 2 Very Slow [3]
G2 (Intermediate) 3% – 20% 2 – 20 Moderate [3]
*G3 (High) ** > 20% > 20 Fast [3]

*A well-differentiated tumor with a Ki-67 over 20% is classified as a “Well-Differentiated NET G3.” It is important not to confuse this with a poorly differentiated NEC, as their treatments and underlying biology are different [4].

Note: If your report has a Ki-67 that places you in G2 but a mitotic rate that places you in G1, doctors usually use the higher grade to be safe [8].

3. Staging: The “Extent” (TNM)

Staging describes how far the tumor has spread. The TNM system is the standard used by doctors:

  • T (Tumor): Measures the size of the tumor and how deep it has grown into the layers of the stomach wall. Confining the tumor to the top layers (mucosa or submucosa) is a positive sign [9][10].
  • N (Node): Indicates if the tumor has spread to nearby lymph nodes.
  • M (Metastasis): Indicates if the tumor has spread to distant organs, most commonly the liver [11].

Your Pathology Audit Checklist

Every G-NET pathology report should ideally include these data points. If any are missing, you should ask your doctor if they can be added through further testing.

  • [ ] Differentiation: (Well-differentiated vs. Poorly-differentiated) [1]
  • [ ] Ki-67 Index: (The percentage, e.g., 4%) [7]
  • [ ] Mitotic Rate: (Number of mitoses per 2mm²) [3]
  • [ ] Tumor Size: (Usually in mm or cm) [10]
  • [ ] Invasion Depth: (How deep it goes into the stomach wall) [9]
  • [ ] Margin Status: (Whether the edges of the removed tissue are clear of “cancer”)
  • [ ] Lymphovascular Invasion: (Whether the tumor has started to enter local blood or lymph vessels)

If Ki-67 or mitotic rate is missing, it is considered essential for modern care. These markers are indispensable for deciding whether you need simple monitoring or more active treatment [7][12].

Common questions in this guide

What is the difference between a well-differentiated NET and poorly differentiated NEC?
Well-differentiated tumors look similar to normal, healthy cells and generally grow slower. Poorly differentiated tumors, known as neuroendocrine carcinomas (NECs), look very abnormal and disorganized, and are highly aggressive.
What does the Ki-67 index mean on my pathology report?
The Ki-67 index is a percentage that measures how fast your tumor cells are dividing. A higher percentage means more cells are actively growing, which helps your care team determine the tumor's grade and how aggressive it might be.
Why is depth of invasion important in a gastric neuroendocrine tumor?
Depth of invasion measures how deeply the tumor has grown into the layers of the stomach wall. Tumors confined to the top mucosal layers usually have a better outlook and may require less aggressive treatment than those that invade deeper tissues like muscle.
What should I do if my Ki-67 or mitotic rate is missing from my pathology report?
If these crucial markers are missing, you should ask your doctor to order an additional stain or manual count on your existing biopsy sample. These numbers are essential for determining your tumor grade and planning the right treatment or monitoring strategy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor 'well-differentiated' (NET) or 'poorly differentiated' (NEC)?
  2. 2.If the Ki-67 index is missing from the report, can we order an immunohistochemical stain to determine it?
  3. 3.What is the specific depth of invasion—is it confined to the mucosal layer, or does it reach the submucosa or muscle?
  4. 4.How do my tumor grade and mitotic rate specifically influence the decision between monitoring and surgery?
  5. 5.Does the report show any 'lymphovascular invasion,' and what does that mean for my risk of spread?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.

    Sorbye H, Baudin E, Perren A

    Endocrinology and metabolism clinics of North America 2018; (47(3)):683-698 doi:10.1016/j.ecl.2018.05.001.

    PMID: 30098724
  2. 2

    Multifocal G1-G2 gastric neuroendocrine tumors: Differentiating between Type I, II and III, a clinicopathologic review.

    Algashaamy K, Garcia-Buitrago M

    World journal of clinical cases 2019; (7(17)):2413-2419 doi:10.12998/wjcc.v7.i17.2413.

    PMID: 31559277
  3. 3

    A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

    Rindi G, Klimstra DS, Abedi-Ardekani B, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(12)):1770-1786 doi:10.1038/s41379-018-0110-y.

    PMID: 30140036
  4. 4

    Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors.

    Yan S, Liu T, Li Y, et al.

    Annals of translational medicine 2019; (7(20)):545 doi:10.21037/atm.2019.09.114.

    PMID: 31807527
  5. 5

    [Current WHO classification (2022) of neuroendocrine neoplasms].

    Buchstab O, Knösel T

    Radiologie (Heidelberg, Germany) 2024; (64(7)):531-535 doi:10.1007/s00117-024-01295-z.

    PMID: 38622292
  6. 6

    New insights into the classification of gastric neuroendocrine tumours, expanding the spectrum of ECL-cell tumours related to hypergastrinaemia.

    La Rosa S, Solcia E

    Histopathology 2020; (77(6)):862-864 doi:10.1111/his.14226.

    PMID: 33190337
  7. 7

    Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms.

    Klöppel G, La Rosa S

    Virchows Archiv : an international journal of pathology 2018; (472(3)):341-349 doi:10.1007/s00428-017-2258-0.

    PMID: 29134440
  8. 8

    Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.

    Broechner A, Maier AD, Mirian C, et al.

    Journal of neuropathology and experimental neurology 2026; (85(3)):253-266 doi:10.1093/jnen/nlaf131.

    PMID: 41267161
  9. 9

    A Modified T-Stage Classification for Gastric Neuroendocrine Tumors.

    Yang T, Fong ZV, Pak L, et al.

    The Journal of surgical research 2022; (270()):486-494 doi:10.1016/j.jss.2021.10.002.

    PMID: 34800795
  10. 10

    Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor.

    Noh JH, Kim DH, Yoon H, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(10)):2495-2502 doi:10.1007/s11605-021-04997-0.

    PMID: 33825119
  11. 11

    Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.

    Lawal IO, Ololade KO, Lengana T, et al.

    Hellenic journal of nuclear medicine 2017; (20(2)):128-133 doi:10.1967/s002449910553.

    PMID: 28697189
  12. 12

    Head-to-head: Should Ki67 proliferation index be included in the formal classification of pulmonary neuroendocrine neoplasms?

    Pelosi G, Travis WD

    Histopathology 2024; (85(4)):535-548 doi:10.1111/his.15206.

    PMID: 38728050

This page explains G-NET pathology terminology for educational purposes. Always review your specific pathology report and test results with your oncologist or gastroenterologist to understand what they mean for your care.

Get notified when new evidence is published on Neuroendocrine tumor of stomach.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.